Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. entered into a Note Purchase Agreement on April 1, 2026 to issue and sell up to $1,250,000 in aggregate principal amount of promissory notes in a private offering. Investors will pay $1,000,000, reflecting a 20% original issue discount.
The Notes bear 0% interest unless an event of default occurs, in which case interest increases to 15% per year. All principal and any default interest are due on the earlier of 12 months from issuance or the closing of a Qualified Financing. While the notes are outstanding, the company has agreed not to incur additional borrowed money debt or grant new liens, and investors receive the right to participate in future securities offerings up to 100% of their note principal.
Wellgistics Health, Inc. has notified stockholders that holders of a majority of its outstanding common stock approved, by written consent, a board-authorized reverse stock split at a ratio between 1-for-25 and 1-for-200, exercisable at the Board's discretion within 12 months of the written consent.
The action was approved by holders representing 66,590,104 votes (approximately 55.32%) of the 120,380,108 shares issued and outstanding as of April 1, 2026. The company will mail this Information Statement on or about April 3, 2026. The Board may file the amendment to effect a reverse split at any time before the end of the 12-month period or decide not to proceed.
Wellgistics Health, Inc. director Marlene Velez has filed an initial Form 3, which is a required statement of her beneficial ownership position in the company’s securities. The filing shows no reported purchases, sales, option exercises, gifts, or other transactions at this time.
Wellgistics Health, Inc. approved by majority written consent a board-authorized reverse stock split in a ratio between 1-for-25 and 1-for-200, with the Board able to set the exact ratio within 12 months.
The action was approved by holders representing 66,590,104 votes (55.32%) of the 120,380,108 shares outstanding as of the Record Date. The company says the Reverse Split is intended to attempt to meet Nasdaq's $1.00 minimum bid requirement; Nasdaq compliance period expires June 8, 2026. The Information Statement will be mailed on or about April 3, 2026. Estimated mailing costs are approximately $10,000. The Board retains discretion not to effect the Reverse Split even after stockholder approval.
Wellgistics Health, Inc. approved by majority written consent an amendment authorizing a forward‑looking reverse split of its Common Stock at a ratio between 1-for-25 and 1-for-200, with the Board authorized to set the exact ratio any time within 12 months of the consent.
The approval was effected by written consent on March 23, 2026; as of that record date the company had 120,380,108 shares issued and outstanding and holders representing 66,590,104 votes (approximately 55.32%) voted in favor. The Board may file the Certificate of Amendment to effect the Reverse Split or elect not to proceed. The company received Nasdaq notice on December 10, 2025 and has a compliance period through June 8, 2026.
Wellgistics Health, Inc. files its annual report describing a fast‑growing healthcare ecosystem built around specialty‑lite pharmaceuticals, wholesale distribution and a digital pharmacy hub. The company operates through Wellgistics Pharmacy, wholesale unit Wellgistics LLC, technology platform DelivMeds and holding entity Wood Sage.
Wellgistics closed the Wellgistics LLC acquisition on August 30, 2024, with consideration including a $10 million closing cash payment, a $15 million promissory note and equity‑based bonuses, later restructured into 3,999,335 restricted shares. The cash payment is now due the earlier of 120 days after its Form S‑1 becomes effective or August 30, 2025. The report highlights its 5P‑Model serving patients, providers, pharmacies, payors and manufacturers, and lists extensive risk factors around integration, reimbursement pressure, competition, regulation, debt and technology reliance.
Wellgistics Health, Inc. entered a three-year Interim Commercialization and Revenue Share Agreement with Kare PharmTech to market, promote and distribute Kare’s KARE Verify eligibility and benefits verification product through Wellgistics’ pharmacy and distribution network.
All net revenue from KARE Verify will be split 50% to Wellgistics and 50% to Kare PharmTech. Wellgistics also secured preferred pricing for medical insurance eligibility and benefits verification services, which it plans to offer immediately via its EinsteinRx AI hub and later integrate into its PharmacyChain platform to support a new revenue stream starting in the second quarter of 2026. The EBV market is cited as growing from $2.39 billion in 2025 to $3 billion in 2030.
Wellgistics Health, Inc. filed a current report highlighting the launch of Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies, including GLP-1 agonist drugs such as Ozempic, Wegovy and Mounjaro.
Forzet is classified as a medical food, is available over the counter, does not require a prescription, and is intended for use under physician supervision. It has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe.
Wellgistics plans to recommend Forzet through its EinsteinRx AI pharmacy hub via point-of-sale pop-ups in its 6,500+ pharmacy network and to feature GLP-1 drugs and Forzet in its growing direct-to-consumer and telehealth offerings. The press release notes estimates that the GLP-1 agonist market could grow from $70 billion in 2025 to $201 billion in 2030.
Wellgistics Health, Inc. entered a court-approved settlement with Silverback Capital Corporation to resolve at least $10,712,734.16 of company liabilities through the issuance of common stock under a Section 3(a)(10) exemption. A Florida court approved the fairness of both the settlement terms and related share issuances.
The settlement allows shares to be issued in tranches by dividing portions of the claim amount by fixed prices between $0.25 and $2.25 per share, with the first $2,250,000 tranche set at $0.25 per share. Wellgistics also agreed to issue 100,000 shares as a settlement fee and 300,000 shares for legal fees. Separately, the company appointed Fortitude Advisors, owned and controlled by Gerald Commissiong, as consulting Chief Business Officer, and announced an expanded partnership with Tollo Health’s TolloCare unit to add GLP-1 and Long COVID telehealth services and a mental health AI app to its platform.
Wellgistics Health, Inc. elected Gary Herman as an independent director effective February 4, 2026, and named him chairman of the Audit Committee. Non‑employee directors receive a $120,000 annual cash retainer, an annual equity award of 60,000 shares of Common Stock, and 200,000 restricted shares vesting over three years at appointment.
The company also entered into an agreement with NFL Alumni Health to develop healthcare and wellness programs using its EinsteinRx AI pharmacy hub and PharmacyChain blockchain platform. The programs will start with former NFL players, then expand to rural communities through a network of more than 6,500 independent pharmacies, focusing on mental health, weight loss, sleep apnea, cardiometabolic disease, pain management, and Long COVID.